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Background: Gastrointestinal (GI) symptoms are seen in majority of patients
with Systemic Sclerosis (SSc) and are a common presenting feature of disease.
Severe GI involvement may lead to malabsorption which represents a poor prog-
nostic factor. Accordingly, a regular monitoring of gastrointestinal tract involve-
ment and nutritional status appears crucial in SSc patients. Previous studies
reported low values of bone mass density (BMD) in SSc patients1. While no spe-
cific relationship has emerged between the two conditions, it’s likely that disease
related GI involvement may contribute to the alterations in BMD.
Objectives: To determine if GI-related clinical status was associated to low bone
density in our cohort of SSc patients.
Methods: Two-hundred-ten unselected SSc patients have been enrolled. The 7-
items UCLA SCTC GIT 2.0 questionnaire and Malnutrition Universal Screening
Tool (MUST) were administered to each patient. A comprehensive medical history
was collected. A blood panel for nutritional status was also performed. T-scores
and Z-scores at lumbar spine, femoral neck, Ward’s and total hip measured by
dual-energy X-ray absorptiometry (GE Lunar Prodigy) were measured.
Results: In our cohort, 86.7% of patients reported some GI symptoms. The mean
UCLAGIT total score was 0.345±0.34 and 51 patients (24.3%) were at risk of mal-
nutrition according to MUST (score 1). 53.7% patients had BMD values<1, and
12.5% had BMD values£2.5 at any of the considered sections. Patients with
reduced BMD (<-1) showed similar levels of selected nutritional blood markers
compared to subjects with normal BMD, including vitamin D and albumin.
Patients with spine T-score <-1 had lower BMI (23.2±3.9 vs 25.2±4.8; p=0.011)
and reported higher UCLA GIT reflux (0.66±0.63 vs 0.42±0.48; p=0.016), disten-
tion (0.80±0.72 vs 0.53±0.56; p=0.15) and total score (0.42+0.37 vs 0.27±0.30;
p=0.006) compared to patients with normal BMD. Similar significant differences
were observed in the same domains for patients with total hip T-score values <-1.
Femoral neck T-score <2.5 was associated with higher UCLA GIT reflux (0.88
±0.78 vs 0.48±0.50; p=0.022), soilage (0.50±0.78 vs 0.14±0.52; p=0.041) and
total score (0.50±0.37 vs 0.31±0.33; p=0.012).
On the other hand, the comparison of patients with severe, moderate and mild
symptoms according to UCLA GIT total score2 showed an association between
progressively lower values of spine and total hip T-score and increasing severity
of GI symptoms (ANOVA for spine T-score: p=0.015; for total hip T-score:
p=0.048).
Patients at risk of malnutrition (MUST score 1) presented significant lower T-
score for all the considered sections (spine and hip) and significant lower total hip
Z-score.
Conclusions: In our SSc cohort gastrointestinal symptoms were frequent and
were associated with low BMD. Considering the heterogeneity of GI involvement,
UCLA SCTC GIT 2.0 emerged as a useful and feasible tool to assess GI involve-
ment and other associated comorbidities. In particular, SSc patients who report
remarkable GI symptoms and are at risk of malnutrition according to MUST may
benefit from a stricter control of BMD to promptly detect osteopenia and
osteoporosis.
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Background: Systemic sclerosis (SSc) is a chronic, multisystem connective tis-
sue disease characterised by by immune dys-regulation, obliterative microvascul-
opathy and fibrosis. Endothelial dysfunction, immune system imbalance and
fibroblast activation constitute the three major factors of the pathogenetic process.
In this context, oxidative stress could play a significant role through direct damage
of endothelial cells and the persistent activation of the immune system.1,2
Objectives: This study investigated the presence of advanced protein oxidation
products (AOPP) in serum of patients with SSc and its correlation with disease’s
features.
Methods: 50 patients with SSc (M:F 1:7, mean age 57.3±11.2 SD, mean duration
of disease 10±9.1 SD years), were screened for AOPP in the serum, using the
AOPP OxiSelect Kit of CELL BIOLABS (San Diego, Ca, USA). Among 50 SSc
patients, 39 had limited cutaneous subset, while 11 had the diffuse one. Anam-
nestic and clinical data were collected for all SSc patients. As a control group 50
consecutive healthy subjects, sex and age matched, were recruited.
Results: We found serum levels of AOPP increased in the SSc group compared
with the controls (p<0.0001) with mean values of 336.9±167.8 mmol/L and 167.5
±59.2 mmol/L, respectively. In addition, higher levels of AOPP directly correlated
with the diffuse cutaneous subset (p=0.0242), presence of digital ulcers
(p=0.005), esophagopathy (p=0.006) and pulmonary fibrosis (p=0.0128).
Conclusions: Serum AOPP levels are significantly higher in patients with SSc
than in controls. In addition, the correlations of AOPP with SSc diffuse cutaneous
subset, digital ulcers, and pulmonary involvement (indicative of progressive dis-
ease and worse prognosis) suggest a possible role of this marker in the identifica-
tion of the cases with worse clinical evolution. The data of this preliminary study
should be confirmed on larger case series and analysed in prospective studies, in
order to understand its eventual usefulness during the follow-up of SSc patients.
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Background: Nailfold videocapillaroscopy (NVC) is a non invasive diagnostic
technique useful for evaluating microvascular status in patients with connective
tissue diseases.1 In systemic sclerosis (SSc) capillary abnormalities, when eval-
uated by NVC, evolve in a clearly defined sequence called the ”scleroderma pat-
terns” (Early, Active, Late).2 On the contrary, mixed connective tissue disease
(MCTD) doesn’t show characteristic either nailfold capillary abnormalities or typi-
cal sequence.1,2 Until today, few studies described the main NVC changes in
MCTD.3
Objectives: To retrospectively study nailfold microangiopathy by NVC in MCTD
patients with a follow-up of three years and to compare capillaries abnormalities
between patients affected by MCTD and SSc.
Methods: Ten patients (mean age 50±19 years) affected by MCTD with Raynaud
phenomenon (Kasukawa’s criteria)4 who performed their first NVC were enrolled.
Among these, complete capillaroscopic and clinical data at three years were avail-
able for 7 patients (disease duration 6.4±4.2 years). Main NVC parameters (abso-
lute number of normal and total capillaries and scores of capillary ramifications,
enlarged capillaries, giant capillaries, microhemorrhages, number of capillaries)
were evaluated by NVC at baseline (T0, first NVC), and after one (T1) and three
years (T3). Possible variations of capillary findings were analysed, along with cor-
relations among capillaroscopic and clinical parameters. Furthermore, we com-
pared main NVC parameters at T0 of ten above-mentioned MCTD patients versus
ten random SSc patients with the same disease duration (6.4±4.2 years) and simi-
lar age (51±17 years). Statistical analysis was performed by non parametric tests.
The patients were receiving different immunosuppressive treatments.
Results: No statistically significant variation of the scores as well as of the abso-
lute value of the above reported capillary parameters was observed during the 3
years of follow-up. No statistically significant correlation was observed between
capillary parameters and MCTD clinical aspects (Raynaud phenomenon, dyspha-
gia, dyspnoea, sclerodactily, sicca syndrome, telangiectasies and arthralgia) at
first visit and during follow-up. The scores of enlarged capillaries and giant capilla-
ries were found significantly higher (p<0.05) in patients with SSc versus MCTD
patients at T0. Moreover, the absolute number of total capillaries and normal capil-
laries were found significantly lower (p<0.05) in SSc patients versus MCTD
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